Evidence map›Paper›PMID 35386254›Full record

ArticleFrontiers in pediatrics2022

Prognostic Observational Analysis of BMI, Leptin, and Adiponectin in Children With Acute Lymphocytic Leukemia Undergoing Remission-Induction Chemotherapy.

Jing Sun, Ru Zhang, Jianjun Tang, Xuedong Wu, Lu Zhu, Haiying Huang, Huimin Chen, Minhua Xiao, Hongfeng Luo, Haiqing Zheng and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Observational
  5. Analysis ofTranslational pediatrics · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Jing SunDepartment of Clinical Nutrition, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Ru ZhangDepartment of Hematology and Oncology, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Jianjun TangDepartment of Anesthesiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xuedong WuDepartment of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Lu ZhuDepartment of Hematology and Oncology, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Haiying HuangDepartment of Hematology and Oncology, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Huimin ChenDepartment of Clinical Nutrition, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Minhua XiaoDepartment of Clinical Nutrition, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Hongfeng LuoDepartment of Clinical Nutrition, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Haiqing ZhengInstitute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Jiaqi ChenDepartment of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Guangzhou Medical University · CNGuangzhou Women and Children Medical Center · CNSouthern Medical University · CNNanfang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The survival rate of children and adolescents with acute lymphoblastic leukemia (ALL) has progressively improved. However, ALL survivors often have adverse effects after treatment, such as an increased risk of obesity. Obesity has been associated with reduced survival. Objective: We investigated the relationship between obesity, adipocytokine levels, and ALL short-term outcomes. Methods: Weight and height were measured, and body mass index (BMI) was calculated at patient diagnosis and discharge. Leptin and Adiponectin levels and Minimal Residual Disease (MRD) were measured before therapy, at days 19 of remission-induction therapy, and at the end of remission-induction therapy (days 46). The relationship between BMI, adipocytokine levels, and MRD was then determined. Results: Compared to the normal BMI group, children with an abnormal increase in BMI had an increase in MRD at day 19 and 46 ( Conclusion: BMI affects the outcome of ALL patients. Early interventions such as regular weight, height monitoring, and dietary assessments should be preferably initiated during remission-induction chemotherapy.

Indexed as

adipocytokinebody mass indexchildhood acute lymphoblastic leukemiaminimal residual disease (MRD)obesityremission-induction chemotherapy

Identifiers

PMID35386254
PMCPMC8978674
OpenAlexW4220693393

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.